Salarius Pharmaceuticals, Inc. (SLRX)

US — Healthcare Sector
Peers: RNTX  ARTL  CRIS  PDSB  PHIO  POAI 

Automate Your Wheel Strategy on SLRX

With Tiblio's Option Bot, you can configure your own wheel strategy including SLRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SLRX
  • Rev/Share 0.0
  • Book/Share 0.0372
  • PB 13.4478
  • Debt/Equity 1.8141
  • CurrentRatio 1.0121
  • ROIC -32.5811

 

  • MktCap 3822795.0
  • FreeCF/Share -2.6162
  • PFCF -0.8782
  • PE -0.1494
  • Debt/Assets 0.048
  • DivYield 0
  • ROE -3.2414

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
SLRX
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025.

Read More
image for news Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
SLRX
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer

Read More
image for news Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

About Salarius Pharmaceuticals, Inc. (SLRX)

  • IPO Date 2015-01-29
  • Website https://www.salariuspharma.com
  • Industry Biotechnology
  • CEO David J. Arthur
  • Employees 2
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.